Predicted to enable dynein heavy chain binding activity and dynein light chain binding activity. Involved in cellular response to nerve growth factor stimulus and negative regulation of neuron projection development. Predicted to be located in centrosome; microtubule; and vesicle. Predicted to be part of cytoplasmic dynein complex and outer dynein arm. Orthologous to human DYNC1I2 (dynein cytoplasmic 1 intermediate chain 2); PARTICIPATES IN mitochondria transport pathway; phagocytosis pathway; vasopressin signaling pathway via receptor type 2; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 2,4-dibromophenyl 2,4,5-tribromophenyl ether; 2,6-dinitrotoluene.
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DYNC1I2 mRNA
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of DYNC1I2 mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of DYNC1I2 mRNA
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of DYNC1I2 mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of DYNC1I2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DYNC1I2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DYNC1I2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DYNC1I2 mRNA
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of DYNC1I2 mRNA more ...
[LDN 193189 co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with FGF2 protein] results in increased expression of DYNC1I2 protein
[sodium arsenite co-treated with sodium arsenite deficiency] results in decreased methylation of DYNC1I2 promoter and [sodium arsenite co-treated with sodium arsenite deficiency] results in increased expression of DYNC1I2 mRNA
Live cell imaging reveals differential modifications to cytoplasmic dynein properties by phospho- and dephosphomimic mutations of the intermediate chain 2C S84.